AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00292591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: comparing vitamin D requirements of pregnant women and their fetuses from 12 weeks' gestation through pregnancy
Study NCT01613794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 20 mg od
Study NCT02746419 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Vessix
Description: Renal denervation using radio-ablation
Study NCT02746419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vessix
Description: Renal denervation using radio-ablation
Study NCT04220775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp Alfa
Description: Given IV
Study NCT04220775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04220775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01019915 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CRT
Description: Insertion of CRT in patients with left bundle branch block. Assessment of skeletal muscle and infalmmatory profile
Study NCT04980209 — intervention group
Intervention type: DEVICE
Intervention: ultrasound evaluation
Description: According to the sequential test, the enrolled patients were divided into ultrasound evaluation group and no ultrasound evaluation group.
Study NCT01676870 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1x4 aerobic interval training
Description: endurance training as walking/running uphill 3 times/week for 16 weeks (2 supervised sessions (treadmill) and 1 at home each week) at 90% of Hfmax. Warm-up 10 min at 70% of maximal heart frequency (Hfmax), 5min cool-down.
Study NCT01676870 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4x4 aerobic interval training
Description: endurance training as walking/running uphill 3 times/week for 16 weeks (2 supervised sessions (treadmill) and 1 at home each week) at 90% of Hfmax. Warm-up 10 min at 70% of maximal heart frequency (Hfmax), 3 min active pause between each interval, 5min cool-down.
Study NCT01676870 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: traditional moderate training
Description: moderate intensity treadmill training (50-70% of HRmax) for a minimum of 30min, 5 times a week for 16 weeks (2 supervised sessions and 3 or more home).
Study NCT02392442 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Investigate the changes in miRNA signatures found in BAL and lung cells from healthy volunteers at baseline and at 6 hours after 1800 of normal Saline installed in six 30 mL aliquots into the left (lingual) and right (middle lobe) lung segments (360 mL total).
Study NCT02392442 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endotoxin
Description: Investigate the changes in miRNA signatures found in BAL and lung cells from healthy volunteers at baseline and at 6, 24, or 48 hours after endotoxin segmental lung challenge.
Study NCT03872115 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDVibe2
Description: The PDVibe2 is owned by Resonate Forward, LLC and will be loaned to Virginia Commonwealth University (VCU) for this project. The device is non-invasive, lightweight, untethered, contains a rechargeable battery, and is worn on both feet and ankles. PDVibe2 delivers vibration when activated by an easy to access switch on the device or by remote. The internal circuitry has been miniaturized, is encased in a small box, and is attached to the ankle using a soft flexible band.
Study NCT04147286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 40mg
Description: 12 weeks of 40 mg atorvastatin therapy per os
Study NCT04147286 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Identical placebo
Study NCT03931824 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRP
Description: A venous blood sample of 8.5 ml were obtained from patients. For the study group, the blood samples were mixed with 1.5 ml ACD-A or sodium citrate to achieve anticoagulation. Resulting material was then centrifugated for 5 minutes with RCF 1200 G speed to clump erythrocytes, and then centrifugated for 10 minutes in same speed to obtain thrombocyte concentrate. 2 ml's of the platelet rich plasma was injected to the shoulder of the subjects. For the sham injection group, same amount of blood was taken and they were given a of waiting time of same duration with the study group, with the resulting preparate being 2 ml's of 0,9% saline instead. PRP solutions were prepared with kits of Easy PRP(Neotec Biotechnology, Istanbul, Turkey).~Injections were done every two weeks, for a total of 3 times. 21 G injection needles with injection technique of posterior approach were used(18, 19). To provide blindness, all injections were done using injectors coated with non transparent tape.
Study NCT03931824 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: All of the patients were also informed about proper positioning and the standard care for the affected extremity. Their process of neurological rehabilitation was not changed, which was 5 days of the week, one session of 45 minutes a day. They were also given a program of standardized ROM exercises, which included passive and active motions.
Study NCT03931824 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise
Description: All of the patients were also informed about proper positioning and the standard care for the affected extremity. Their process of neurological rehabilitation was not changed, which was 5 days of the week, one session of 45 minutes a day. They were also given a program of standardized ROM exercises, which included passive and active motions.
Study NCT01484041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib
Description: Dovitinib at the recommended Phase 2 dose for 5 consecutive days followed by a 2-day rest
Study NCT01484041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitors
Description: Patients will receive one of the aromatase inhibitors either anastrozole 1 mg po daily, letrozole 2.5 mg po daily, or exemestane 25 mg po daily
Study NCT01973569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: denosumab
Description: denosumab administered subcutaneously
Study NCT01973569 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo administered subcutaneously to match denosumab
Study NCT00427947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine/placebo
Description: Continuous sciatic nerve bloc
Study NCT00427947 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ropivacaine/placebo
Description: Continuous sciatic nerve bloc
Study NCT02906904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Case Intervention
Description: 24-hour sleep deprivation protocol, polysomnographic monitoring of the recovery sleep, triggering of parasomniac episodes by auditory stimulations, thermoalgic stimulation (Modulator Sensory Analyzer Thermal Stimulator®) during wakefulness, parasomniac episodes, NREM stage 2 ans SWS
Study NCT02906904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Intervention
Description: 24-hour sleep deprivation protocol, polysomnographic monitoring of the recovery sleep, thermoalgic stimulation (Modulator Sensory Analyzer Thermal Stimulator®) during wakefulness, NREM stage 2 ans SWS
Study NCT03714620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine 0.15 mg/kg vs. 0.3 mg/kg IVPB over 15 minutes
Study NCT03350165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877
Description: 0.2mg tablet
Study NCT03350165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: K-877 matching placebo tablet
Study NCT00082342 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Phoressor II (IOMED)
Description: sham stimulation
Study NCT00082342 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phoressor II (IOMED)
Description: real tDCS stimulation
Study NCT04045548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone
Description: 1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 6 hours before IUD insertion.
Study NCT04045548 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one tablet of placebo inserted by the study nurse 6 hours before IUD insertion.
Study NCT03475680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sennosides colonic preparation
Description: Mechanical bowel preparation :~Sennosides colonic preparation (X-PREP)~1 per day, on day -2 and day -1
Study NCT03475680 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sennosides colonic preparation
Description: Mechanical bowel preparation :~Sennosides colonic preparation (X-PREP)~1 per day, on day -2 and day -1
Study NCT03475680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Gentamycin
Description: Gentamycin 80 mg, 4 per day, on day -2 and day -1; Liquid forms in individual vials
Study NCT03475680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Ornidazole
Description: Oral Ornidazole :~Ornidazole~1 g per day (2 tablet per day), on day -2 and day -1; In tablets
Study NCT03475680 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral placebo Gentamycin
Description: Placebo for oral gentamycin :~Same presentation as oral gentamycin x4 per day on day -2 and day -1
Study NCT03475680 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral placebo Ornidazole
Description: Placebo for oral Ornidazole :~Same presentation as oral ornidazole~1g per day (2 tablet per day) on day -2 and day -1
Study NCT04406974 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery or treatment for local recurrence
Description: Surgery or treatment for local recurrence
Study NCT04406974 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery for advanced colorectal cancer
Description: Surgery for advanced colorectal cancer
Study NCT02970916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI+aflibercept
Description: Aflibercept: 4 mg/kg administered intravenous infusion on day 1~FOLFIRI regimen immediately after aflibercept:~Irinotecan:180 mg/m2 intravenous infusion, folinic acid (dl racemic): 400 mg/m2 intravenous infusion, followed by 5-fluorouracil (5-FU): 400 mg/m2 intravenous bolus, followed by 5-FU: 2400 mg/m2 continuous intravenous infusion over 46 hours.~\* folinic acid: 400 mg/m² (racémic) or 200 mg/m² (L-form)
Study NCT01966601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRV027 Dose #1
Description: TRV027 continuous intravenous infusion Dose #1
Study NCT00915005 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Therapy
Description: Group 2: 74 Gy in 2 CGE per fraction given 5 days a week for about 7 1/2 weeks.~Group 3: 66 Gy with conventional fractionation given 5 days a week for about 6-7 1/2 weeks.~Each daily treatment should take about 20-30 minutes to complete.
Study NCT04220775 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT03815552 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eversense Continuous Glucose Monitoring
Description: The Eversense Continuous Glucose Monitoring System is a glucose monitoring device intended to continually measure interstitial fluid glucose levels in individuals with diabetes for the operating life of the sensor.The System comprises a sensor and a transmitter. The small sensor will be subcutaneously inserted in the arm.The transmitter reads glucose data from the subcutaneous sensor.
Study NCT06638736 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Wound Closure with sutures vs staples
Description: Closure of the wound with either sutures or staples depending upon the study arm
Study NCT00915005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 50 mg/m2 by vein 1 time each week for 7 weeks.
Study NCT04409587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspart
Description: A population of well controlled patients with type 1 diabetes who are experienced in the use of both Continuous Subcutaneous Insulin Infusion (CSII) and Continuous Glucose Monitor (CGM) was chosen in order to assess the effect of the change in glycemic profile using two different methods of basal insulin delivery. Allowing the subjects to use their insulin pumps for bolus insulin delivery, as they are accustomed, will minimize the chances of skipping meal boluses and correction doses.~Replacing basal insulin delivery by CSII with a single daily injection of degludec will add minimal, if any, treatment burden which will be offset by potential therapeutic benefits. These benefits include the potential for reduced glycemic variability and the elimination of the risk of hyperglycemia and DKA with basal insulin interruption which can occur with infusion set occlusion or disgorging inherent to Continuous Subcutaneous Insulin Infusion.
Study NCT01305876 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: yoga intervention
Description: yoga session 2 x week over 3-1/2 months
Study NCT01899326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desipramine Hydrochloride
Description: Given PO
Study NCT01899326 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given PO
Study NCT01899326 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04063670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Intervention
Description: Peri-operative video series focusing on expanded education and coping skills before and after scoliosis surgery for adolescent idiopathic scoliosis
Study NCT04063670 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Routine, Standard-of-Care
Study NCT02452879 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: For the deep needling acupoint group, needle on bilateral BL33 50-60mm with a 60°angle. A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3). Needle with 75mm long needle. An electric stimulator is put on. SDZ-V Hua Tuo Brand electric stimulator (produced by Suzhou Medical Instrument Co.Ltd). continuous wave(CW), 10Hz. Stop turning up the current intensity when patients could not stand. 3 times a week. Once every other day The treatment period lasts eight weeks. totally 24 times.30min/time.
Study NCT02452879 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Electroacupuncture
Description: with the patient in the prone position. The acupoint routine disinfection of skin, and then the fixed pad is adhered on the acupoint. The 1.5 inches blunt tip needle pierce through the fixed pad, then it reaches the surface of the skin, uniform lifting thrusting and twirling all 3 times but do not pierce the skin. Then connect the electric acupuncture apparatus with special power supply wire electrode (special power line as the middle wire cut, looks as normal; that electroacupuncture instrument display connected to the state, but the actual without electricity), in the bilateral Zhongliao points, Hui Yang points on the needle handle; the period of treatment and the other manipulation of the placebo group are same as the deep needling acupoint group.
Study NCT02452879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin Succinate
Description: made by the Anse Tailai Pharmaceutical (China) R \& D limited company) 5mg / tablet
Study NCT06338423 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vacuum mattress
Description: vacuum mattresses used to better positioning of the patient
Study NCT06338423 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Mattress
Description: Standard Mattress
Study NCT01966601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRV027 Dose #2
Description: TRV027 continuous intravenous infusion Dose #2
Study NCT01966601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRV027 Dose #3
Description: TRV027 continuous intravenous infusion Dose #3
Study NCT03126630 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anetumab Ravtansine
Description: Given IV
Study NCT03126630 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03126630 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03126630 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Given IV
Study NCT03126630 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT03126630 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03126630 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01966601 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo continuous intravenous infusion
Study NCT00915005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 2 by vein 1 time each week for 7 weeks.
Study NCT03912922 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activity regime
Description: Activity regime of 4 days followed by a test day.
Study NCT04151537 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personal Activity Intelligence
Description: The intervention group is provided with a PAI monitor (wristband) with a user interface (app) to track their own PAI level and are instructed to obtain at least 100 PAI on a weekly basis.
Study NCT04151537 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Guidelines
Description: The control group is recommended to follow national PA guidelines, meaning 150 minutes of moderate-intensity PA or 75 minutes of vigorous-intensity PA, or a combination there of. The control group is provided with a PAI monitor (wristband) without any user interface and are thus blinded to track their own PAI level.
Study NCT01630044 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TNM device
Description: Non-invasive neurostimulator, home-use treatment for up to 43 days.
Study NCT04511234 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagicTouch PTA sirolimus drug coated balloon (DCB)
Description: For participants randomised to MagicTouch PTA sirolimus DCB, following successful plain balloon angioplasty of the arterial lesion, (defined as \<30% residual stenosis after treatment at rated burst pressure of the angioplasty balloon), MagicTouch PTA sirolimus coated balloon will be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty.
Study NCT04511234 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: POBA standard balloon
Description: For participants randomised to the standard balloon angioplasty group, a placebo standard balloon which is identical to the SCB will also be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty.
Study NCT02017678 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JX-594
Description: 5 weekly IV infusions of JX-594 followed by laparoscopy and biopsy on day 10 or 38.
Study NCT04443127 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Training Session
Description: VR based motor priming intervention will be given for 16 sessions, comprising of 45 minutes, 4 times/week for the duration of 4 weeks on two VR environments.
Study NCT04443127 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Motor-Relearning Program
Description: Motor-Relearning Program intervention will be given for 16 sessions, comprising of 45 minutes, 4 times/week for the duration of 4 weeks on two VR environments.
Study NCT01831934 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone®
Description: This vaccine is given intramuscularly, either the 2010-2011 or 2011-2012 vaccination was given as appropriate
Study NCT01255397 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Male Infertility Protocol
Description: 1. Healthy women with a regular cycle between 28 and 35 days. For the man, an abnormal sperm exam.~2. Daily US examinations from day 8 of the menstrual cycle. Excluding weekends.~3. When the leading follicle is 14 mm she will be given 100 units puregon and orgalutran,once daily until the leading follicle is at least 16 mm at which point she will be given ovitrelle at 21:00.~4. 35 hours after Ovitrelle at 8:00 the husband will present a sperm sample for analysis. A pelvic US will be done to the wife.~   1. If the follicle has collapsed than IUI will be performed~  2. It the total motile sperm count is above 5 million sperm/ml then IUI will be done~  3. If the total motile sperm count is below 5 million and the follicle has not collapsed, proceed to oocyte aspiration and ICSI~6) ICSI and embryo transfer performed on the same day. 7) Luteal support: Endometrin 100 mg twice a day following IUI\\ET until 6 weeks gestation Protocol can be repeated for up to 3 cycles per couple.
Study NCT01364571 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SA4Ag vaccine low dose
Description: Subjects receive 1 intramuscular injection (0.5 mL) of the low dose level of the SA4Ag vaccine.